CT-Guided HDR Brachyterapy in Patients with Advanced Non-Resectable and Progressive NEN with Liver Bulky Disease. Pilot Study Abstract #2240

Introduction: CT-Guided HDR Brachyterapy is a new method used for liver metastases treatment.
Aim(s): The aim of the study was the evaluation of CT (fluoroscopy) guided application of High Dose Rate (HDR) brachytherapy in patients with non-resectable, progressive NEN, with liver involvement.
Materials and methods: 9 patients, 6 males, all with heavy pretreatment history, with a few therapy regiments, mean age 52.0. GEP-NEN seven, single atypical carcinoid (AC) and malignant paraganglioma (PGL1). All with liver involvement, additionally 4 of them had secretory tumors. There were NETG1 (1), G2 (7) and single NETG3. Overall 15 HDR proceedings were conducted. The clinical and radiological evaluation (RECIST 1.0) were used to assess efficacy. PFS and OS during clinical follow-up were calculated using Kaplan-Meier. AEs (CTCAE 4.0) and the frequency of occurrence of radiotherapy related early morbidity using RTOG.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dariusz Kieszko

To read results and conclusion, please login ...

Further abstracts you may be interested in

#14 Radioguided surgery in NET: First impression with Ga-68 labeled somatostatin analogues
Introduction: Neuroendocrine tumors (NET) constitute a heterogenous group of neoplasms. The development of Gallium-68-labeled somatostatin analogues, such as DOTA-NOC or DOTA-TOC, PET/CT have dramatically improved the diagnosis of neuroendocrine tumors. Surgery remains the treatment of choice for localized disease as well as metastatic disease. The aims of surgery are: improvement of symptoms, reduction of tumor mass / burden and to give better quality of life to patients. Recurrent laparotomies often lead to multiple adhesions and altered anatomy. So it is increasingly difficult for imaging physicians and surgeons to separate non-malignant from malignant tissue.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
#169 Radio guided surgery in neuroendocrine tumours using 68Ga-labeled somatostatin analogs – a pilot study.
Introduction: Radioguided surgery (RGS) is an intraoperative localizing technique for the detection of cancer tissue using tumor-specific radionuclides.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Daniel Kaemmerer
#444 Gallium 68 DOTATATE PET CT Assessment of Patients (pts.) with Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs): First Experience in a Multidisciplinary Team in Argentina (Argentum Group)
Introduction: 68Ga-DOTATATE PET CT offers higher resolution than other scintigraphic techniques in terms of localization of the primary tumor and staging of GEP NETs. Different reports in the literature suggest increased sensitivity but clear consensus about indication in neuroendocrine tumors is unclear.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Juan O'Connor
Authors: Eleta M, Pesce V, Bestani C, O'Connor J, ...
#2268 Efficacy of Octreotide LAR in Treatment of Naive Patients with Advanced, Non-Resectable Well and Moderate Differentiated Pancreatic Neuroendocrine Neoplasms (p-NENs)
Introduction: SSA are the first line therapy in well differentiated pNET
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Md, PhD Agnieszka Kolasińska-Ćwikla
#2300 Clinical Use of Lanreotide AG as Initial Therapy in Patients with Advanced, Non-Resectable Well (G1) and Moderate (G2) Differentiated Pancreatic Neuroendocrine Neoplasms (p-NEN)
Introduction: Lanreotide AG currently is used as standard initial therapy in NETG1 & G2 pancreatic NEN with Ki-67<10%.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD Jaroslaw Ćwikła